Inhibiting LV remodeling-the need for a targeted approach

Nature Reviews Cardiology

Volumn 8, Issue 5, 2011, Pages 248-249

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ALISKIREN; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ACUTE HEART INFARCTION; ARTICLE; DISEASE COURSE; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE; METABOLISM; MOLECULARLY TARGETED THERAPY; NOTE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; MYOCARDIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 79955477301     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.48     Document Type: Article

References (10)

1. McDonald, K. M. et al. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans. Assoc. Am. Physicians 103, 229-235 (1990).
2. St John Sutton, M. et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89, 68-75 (1994).
3. Pfeffer, M. A. et al. on behalf of the SAVE Investigators. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327, 669-677 (1992).
4. Gradman, A. H. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012-1018 (2005). (Pubitemid 40354519)
5. Solomon, S. D. et al. for the Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction. Eur. Heart J. doi:10.1093/eurheartj/ehq522.
6. Cohn, J. N., Ferrari, R. & Sharpe, N. on Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 35, 569-582 (2000). (Pubitemid 30167013)
7. Sharpe, N. et al. Early prevention of left ventricular dysfunction following myocardial infarction with angiotensin converting enzyme inhibition. Lancet 337, 872-876 (1991).
8. Hayashi, M. et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107, 2559-2565 (2003). (Pubitemid 36628936)
9. Krum, H. et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur. J. Heart Fail. 6, 937-945 (2004). (Pubitemid 39536310)
10. Taylor, A. L. et al. for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2049-2057 (2004).